The suppression of DLK1 expression resulted in a less aggressive MDS phenotype, which suggests that the upregulation of DLK1 expression may play an oncogenic role in CD34+CD38− bone marrow cells. The gene discussed is CD38; the disease is myelodysplastic syndrome.